Updates ·
Health notices · Sunday 20 September
3 notices from the agencies today, in plain words, each with the original linked.
FDA approval of fexofenadine hydrochloride for allergy symptom relief
Food and Drug Administration (FDA) · Approval
If you have hay fever or other upper respiratory allergies, this FDA-approved medicine is intended to temporarily relieve symptoms like runny nose, itchy or watery eyes, sneezing, and itching of the nose or throat.
This matters if your main problem is these allergy symptoms, because the approved use is symptom relief during flare-ups.
Bundibugyo virus outbreak expanded in DR Congo
WHO · Outbreak
The World Health Organization says the Bundibugyo virus outbreak in the Democratic Republic of the Congo has expanded to Kayna in North Kivu, bringing the total to 61 affected health zones.
As of 7 September 2026, 6,757 confirmed cases and 3,267 deaths have been reported, with a high case-fatality ratio. Transmission is described as variable, with some areas still seeing increasing cases.
If you live in affected areas of the Democratic Republic of the Congo, this means higher risk of the disease spreading, especially where case detection is delayed or where people can’t get early, adequate care.
FDA class II notice for sildenafil citrate ingredient sold for compounding
FDA · Recall
If you use a compounded medicine that contains sildenafil citrate USP from Shoolin Pharma Chem LLP, this FDA Class II notice may affect you.
The notice says CGMP deviations were found during an FDA inspection. “CGMP” are manufacturing quality standards meant to ensure products are made consistently.